PR Newswire BiotechOriginal article
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Data ReadoutpositiveTREMFYAPositive
AI Analysis
Summary
Johnson & Johnson announced that TREMFYA (guselkumab) is the first IL-23 inhibitor to demonstrate significant improvement in spinal pain and stiffness in a landmark axial psoriatic arthritis study, meeting primary and major secondary endpoints with MRI-confirmed inflammation reduction.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Met primary and major secondary endpoints in axial PsA study, showing significant improvement in spinal pain, stiffness, and MRI-confirmed inflammation
Importance:7/10
Sentiment:
0.85
IL-23 inhibitorpsoriatic arthritisaxial PsAlandmark studyMRI assessmentspinal inflammation
Related Companies
Read the original article
Published by PR Newswire Biotech on September 25, 2026 11:30 AM